Table 1.
Demographic and clinical characteristics of participants. Values are given as mean (±SD). For the four neuropsychological tests denoted by asterisks (*) data were available only for 13 out of 17 PD patients and 13 out of 15 controls.
| PD patients | Healthy controls | t-test | p-value | |
|---|---|---|---|---|
| Gender | 9 males, 8 females | 5 males, 10 females | t(29.83) = 1.11 | 0.28 |
| Age | 66.24 (5.68) | 63.20 (4.43) | t(29.58) = 1.69 | 0.10 |
| Education | 14.50 (2.82) | 13.73 (2.44) | t(29.95) = 0.77 | 0.44 |
| MoCA* | 27.08 (1.98) | 26.92 (2.53) | t(22.67) = 0.17 | 0.86 |
| Boston Naming Test* | 28.54 (1.20) | 28.69 (1.25) | t(22.94) = 2.97 | 0.10 |
| WAIS-IV Similarities* | 23.92 (4.03) | 27.00 (5.02) | t(22.21) = 0.92 | 0.35 |
| Semantic Verbal Fluency (animals)* | 25.62 (6.95) | 27.92 (5.19) | t(23.96) = 0.10 | 0.75 |
| Disease duration (by 2018) | 2.82 (1.67) | |||
| Calculated H&Y | 2.63 (0.61) | |||
| UPDRS total | 34.13 (10.80) | |||
| Levodopa equivalent daily dose LEDD (mg) | 376.96 (209.60) |